New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research

  New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor
                       Experiments in Disease Research

BD LSRFortessa™ X-20 Cell Analyzer to Support Up to Five Lasers and 20
Parameters Simultaneously

PR Newswire

SAN JOSE, Calif., June 19, 2013

SAN JOSE, Calif., June 19, 2013 /PRNewswire/ -- BD Biosciences, a segment of
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, today announced the launch of the BD LSRFortessa™ X-20
Cell Analyzer, the latest in its line of high-performance research flow
cytometers.

The BD LSRFortessa X-20 Cell Analyzer delivers high-performance multicolor
analysis with the most compact footprint in its class at just 30" x 29" (76.2
X 73.7 cm) and a height of 30" (76.2 cm). Recognizing that space is a valuable
commodity in today's research environment, BD Biosciences designed the BD
LSRFortessa X-20 Cell Analyzer to be compact without compromising the power
needed.

Offering a new level of flexibility, the analyzer can be configured with up to
five lasers to detect up to 20 parameters simultaneously. While popular laser
choices include blue, red, violet, yellow-green and UV, a wide range of up to
34 available laser choices are available as excitation sources. Each
excitation source is supported by new polygon detector arrays, and each
polygon can support up to eight detectors for maximum flexibility in optical
configuration.

The BD LSRFortessa X-20 Cell Analyzer is designed by BD's special order
program that enables customers to configure BD flow cytometers and cell
sorters to fit precise research and assay needs. This program is tailored to
meet the needs of researchers at the leading edge of biomedical discovery. The
platform is also supported by a full range of BD Biosciences reagents.

"The new BD LSRFortessa X-20 Cell Analyzer will enable researchers to conduct
complex experiments with the additional parameters and increased sensitivity
they need," said Alberto Mas, President, BD Biosciences. "Uncovering dim
staining and rare cell populations is extremely valuable to complex multicolor
assays, which are tools for advanced disease or drug development research."

About BD

BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.

Contact:
Jamie Yacco
Public Relations
(201) 847-4796
Jamie_Yacco@bd.com

SOURCE BD-Becton Dickinson

Website: http://www.bd.com